Wong Ningyan, Yeo Khung Keong
Department of Cardiology, National Heart Centre Singapore Singapore.
Circ Rep. 2019 Sep 28;1(10):397-400. doi: 10.1253/circrep.CR-19-0074.
In the United States and Europe, percutaneous edge-to-edge repair of the mitral valve with the MitraClip device for patients with severe degenerative mitral regurgitation who are at prohibitive surgical risk has been well-established. Recent randomized controlled trials have also demonstrated significant clinical benefits with the use of the device in selected patients with functional mitral regurgitation. Thus far, >80,000 patients in more than 50 countries have undergone the MitraClip procedure. Despite the exponential growth worldwide, the rate of MitraClip adoption in Asia has been more gradual. In addition, very few publications describe the use of MitraClip in Asian populations. This review aims to describe the Asian experience with the MitraClip device and the challenges faced.
在美国和欧洲，对于手术风险极高的重度退行性二尖瓣反流患者，使用MitraClip装置进行经皮缘对缘二尖瓣修复术已得到充分确立。近期的随机对照试验也表明，在选定的功能性二尖瓣反流患者中使用该装置具有显著的临床益处。迄今为止，50多个国家的8万多名患者接受了MitraClip手术。尽管在全球范围内呈指数级增长，但MitraClip在亚洲的采用率增长较为缓慢。此外，很少有出版物描述MitraClip在亚洲人群中的使用情况。本综述旨在描述亚洲使用MitraClip装置的经验以及所面临的挑战。
